What's breaking now, across thousands of outlets.
NeuroScientific has locked in a key meeting with the US FDA for its StemSmart technology aimed at treating refractory Crohn’s disease in a planned Phase 2 trial.
We haven't written up this one. The Sydney Morning Herald has the full story — the link below goes straight to it.
FDA officials uncovered unhygienic conditions, absence of technical staff, and inadequate raw material testing protocols at multiple manufacturing facilities.
Dubai: Egypt’s Health Ministry has revoked the licences of three blood banks at private hospitals after inspections uncovered serious violations that authorities said posed a direct threat to public…
Artificial intelligence is often framed as the technology that suddenly changed drug discovery. But that narrative misses an important truth: computational, or in silico, drug discovery did not begin…
About 90 per cent of the patients using MediSave at Regency Specialist Hospital in Johor Bahru are women, with maternity-related care among the most common treatments.
